Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (97)	1/9/2001 10:37:13 AM
From: nigel bates	Read Replies (1) \| Respond to of 1022

And not to be outdone, ABGX announce two (extensions of deals)... Jan. 9 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) announced today the inclusion of up to 10 additional antigen targets under an eight-year extension of its human antibody collaboration with Pfizer, Inc. (NYSE: PFE - news), raising the possible total product candidates to 15. Pfizer will be responsible for product development, manufacturing and marketing of any products developed through the collaboration. Abgenix will receive a fee to extend the agreement, and could continue to receive for each product, potential research fees, a license fee and milestone payments, plus royalties on any future product sales. This represents the second expansion of Abgenix's research collaboration with Pfizer, which began in December 1997 to provide Pfizer a license to XenoMouse(TM) technology for the generation of fully human antibodies to Pfizer's antigen targets. The original agreement for three antibody product candidates was expanded in February 2000 to include two additional antibody product candidates. In October 2000, the collaboration with Pfizer produced the first antibody product candidate from a XenoMouse technology collaboration in which an IND was filed with the FDA. ``We are pleased with Pfizer's commitment to add ten new targets to our collaboration,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``Pfizer was our first XenoMouse partner and we are encouraged by their success with the technology.'' Jan. 9 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) announced today that it has extended its research collaboration, option and license agreement with Amgen, Inc. (Amgen). Under the extended agreement, Abgenix will use its XenoMouse(TM) technology to generate fully human monoclonal antibodies to antigen targets supplied by Amgen during the collaboration's five-year term. As in the terms of the April 1999 agreement, Abgenix will receive research payments and could receive milestone and license payments, plus royalties on any future product sales by Amgen. Amgen will be responsible for product development, manufacturing, and commercialization of any products developed through the collaboration. ``We are pleased to expand existing relationships with our customers,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``This commitment by Amgen exemplifies the growing interest for antibody therapeutics among leading biotechnology companies.'' ``We are pleased to extend our relationship with Abgenix,'' said Amgen executive vice president and head of research, Dennis M. Fenton, Ph.D. ``This extended agreement provides Amgen with access to Abgenix's fully human monoclonal antibody technology, which is a good strategic fit for our overall antibody strategy.''